Literature DB >> 22101011

ßarrestin1-biased agonism at human δ-opioid receptor by peptidic and alkaloid ligands.

Benjamin Aguila1, Laurent Coulbault, Audrey Davis, Nicolas Marie, Ahmed Hasbi, Florian Le bras, Géza Tóth, Anna Borsodi, Vsevolod V Gurevich, Philippe Jauzac, Stéphane Allouche.   

Abstract

We have previously reported on the differential regulation of the human δ-opioid receptor (hDOR) by alkaloid (etorphine) and peptidic (DPDPE and deltorphin I) ligands, in terms of both receptor desensitization and post-endocytic sorting. Since ßarrestins are well known to regulate G protein-coupled receptors (GPCRs) signaling and trafficking, we therefore investigated the role of ßarrestin1 (the only isoform expressed in our cellular model) in the context of the hDOR. We established clonal cell lines of SK-N-BE cells over-expressing ßarrestin1, its dominant negative mutant (ßarrestin1(319-418)), and shRNA directed against endogenous ßarrestin1. Interestingly, both binding and confocal microscopy approaches demonstrated that ßarrestin1 is required for hDOR endocytosis only when activated by etorphine. Conversely, functional experiments revealed that ßarrestin1 is exclusively involved in hDOR desensitization promoted by the peptides. Taken together, these results provide substantial evidence for a ßarrestin1-biased agonism at hDOR, where ßarrestin1 is differentially involved during receptor desensitization and endocytosis depending on the ligand.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22101011      PMCID: PMC3392209          DOI: 10.1016/j.cellsig.2011.10.018

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  40 in total

1.  Desensitization, internalization, and signaling functions of beta-arrestins demonstrated by RNA interference.

Authors:  Seungkirl Ahn; Christopher D Nelson; Tiffany Runyan Garrison; William E Miller; Robert J Lefkowitz
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-11       Impact factor: 11.205

Review 2.  Beta-arrestin-biased ligands at seven-transmembrane receptors.

Authors:  Jonathan D Violin; Robert J Lefkowitz
Journal:  Trends Pharmacol Sci       Date:  2007-07-20       Impact factor: 14.819

3.  Arrestin2 and arrestin3 are differentially expressed in the rat brain during postnatal development.

Authors:  E V Gurevich; J L Benovic; V V Gurevich
Journal:  Neuroscience       Date:  2002       Impact factor: 3.590

4.  Differential sorting of human delta-opioid receptors after internalization by peptide and alkaloid agonists.

Authors:  Nicolas Marie; Isabelle Lecoq; Philippe Jauzac; Stéphane Allouche
Journal:  J Biol Chem       Date:  2003-04-02       Impact factor: 5.157

5.  beta -Arrestins regulate protease-activated receptor-1 desensitization but not internalization or Down-regulation.

Authors:  May M Paing; Amy B Stutts; Trudy A Kohout; Robert J Lefkowitz; JoAnn Trejo
Journal:  J Biol Chem       Date:  2001-11-02       Impact factor: 5.157

6.  In vitro and in vivo pharmacological profile of UFP-512, a novel selective delta-opioid receptor agonist; correlations between desensitization and tolerance.

Authors:  B Aguila; L Coulbault; M Boulouard; F Léveillé; A Davis; G Tóth; A Borsodi; G Balboni; S Salvadori; P Jauzac; S Allouche
Journal:  Br J Pharmacol       Date:  2007-11-05       Impact factor: 8.739

7.  A unique mechanism of beta-blocker action: carvedilol stimulates beta-arrestin signaling.

Authors:  James W Wisler; Scott M DeWire; Erin J Whalen; Jonathan D Violin; Matthew T Drake; Seungkirl Ahn; Sudha K Shenoy; Robert J Lefkowitz
Journal:  Proc Natl Acad Sci U S A       Date:  2007-10-09       Impact factor: 11.205

8.  Different kinases desensitize the human delta-opioid receptor (hDOP-R) in the neuroblastoma cell line SK-N-BE upon peptidic and alkaloid agonists.

Authors:  Nicolas Marie; Benjamin Aguila; Ahmed Hasbi; Audrey Davis; Philippe Jauzac; Stéphane Allouche
Journal:  Cell Signal       Date:  2008-02-19       Impact factor: 4.315

9.  beta-arrestin-biased agonism at the beta2-adrenergic receptor.

Authors:  Matthew T Drake; Jonathan D Violin; Erin J Whalen; James W Wisler; Sudha K Shenoy; Robert J Lefkowitz
Journal:  J Biol Chem       Date:  2007-12-17       Impact factor: 5.157

10.  Regulation of arrestin binding by rhodopsin phosphorylation level.

Authors:  Sergey A Vishnivetskiy; Dayanidhi Raman; Junhua Wei; Matthew J Kennedy; James B Hurley; Vsevolod V Gurevich
Journal:  J Biol Chem       Date:  2007-09-11       Impact factor: 5.157

View more
  6 in total

Review 1.  Ligand-directed signalling within the opioid receptor family.

Authors:  Amynah A Pradhan; Monique L Smith; Brigitte L Kieffer; Christopher J Evans
Journal:  Br J Pharmacol       Date:  2012-11       Impact factor: 8.739

2.  Tolerance to high-internalizing δ opioid receptor agonist is critically mediated by arrestin 2.

Authors:  Ana Vicente-Sanchez; Isaac J Dripps; Alycia F Tipton; Heba Akbari; Areeb Akbari; Emily M Jutkiewicz; Amynah A Pradhan
Journal:  Br J Pharmacol       Date:  2018-06-07       Impact factor: 8.739

3.  In vivo properties of KNT-127, a novel δ opioid receptor agonist: receptor internalization, antihyperalgesia and antidepressant effects in mice.

Authors:  C Nozaki; H Nagase; T Nemoto; A Matifas; B L Kieffer; C Gaveriaux-Ruff
Journal:  Br J Pharmacol       Date:  2014-12       Impact factor: 8.739

Review 4.  Opioid receptor desensitization: mechanisms and its link to tolerance.

Authors:  Stéphane Allouche; Florence Noble; Nicolas Marie
Journal:  Front Pharmacol       Date:  2014-12-18       Impact factor: 5.810

Review 5.  Biased Opioid Ligands.

Authors:  Abdelfattah Faouzi; Balazs R Varga; Susruta Majumdar
Journal:  Molecules       Date:  2020-09-16       Impact factor: 4.411

6.  Behavioral Characterization of β-Arrestin 1 Knockout Mice in Anxiety-Like and Alcohol Behaviors.

Authors:  Meridith T Robins; Terrance Chiang; Jennifer N Berry; Mee Jung Ko; Jiwon E Ha; Richard M van Rijn
Journal:  Front Behav Neurosci       Date:  2018-03-20       Impact factor: 3.558

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.